Precision BioSciences, Inc. Common Stock (DTIL)
Precision BioSciences, Inc. (DTIL) is a biotechnology company focused on developing gene editing technologies to create innovative therapies for various genetic diseases and cancers. Founded on the proprietary ARCUS genome editing platform, the company aims to deliver precise and durable genetic modifications to improve patient outcomes.
Company News
The CAR T-cell therapy pipeline is experiencing significant momentum, with over 180 companies actively developing more than 200 pipeline therapies. The report highlights promising pipeline candidates and recent advancements in the field, indicating the growing potential of this revolutionary cancer treatment approach.
The mean of analysts' price targets for Precision BioSciences (DTIL) points to a 200.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
In the latest quarter, 4 analysts provided ratings for Precision BioSciences (NASDAQ:DTIL), showcasing a mix of bullish and bearish perspectives. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferen...
These exchange-traded funds track companies in this biotech space.
Which penny stocks are you watching right now? The post Looking For the Best Penny Stocks to Buy? 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.